PI: S. Parikh; Co-investigators: F. Aweeka, G. Dorsey, M. Kamya, F. Nosten et al
Start Date: March 2008, End Date: analysis ongoing
Funded by: Novartis, Inc, Holley-Cotec PharmaceuticalsThis study in very young children (aged 4 months to 2 years) has been based in Tororo, Uganda where 300 HIV infected and HIV uninfected children were enrolled for collection of PK samples for lumefantrine and piperaquine. Serial PK samples were collected and the data generated will provide information on drug disposition and the relationship between drug exposure and outcomes. In addition, the impact of factors such as weight and concomitant medications on PK exposure will also be evaluated. Analysis for this study is ongoing.